Mountain Pacific Investment Advisers LLC Sells 2,159 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mountain Pacific Investment Advisers LLC reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 136,451 shares of the medical research company's stock after selling 2,159 shares during the period. Charles River Laboratories International accounts for 1.5% of Mountain Pacific Investment Advisers LLC's portfolio, making the stock its 26th biggest holding. Mountain Pacific Investment Advisers LLC owned 0.28% of Charles River Laboratories International worth $20,539,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. QRG Capital Management Inc. raised its position in shares of Charles River Laboratories International by 12.7% during the 1st quarter. QRG Capital Management Inc. now owns 1,557 shares of the medical research company's stock valued at $234,000 after purchasing an additional 175 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Charles River Laboratories International by 13.1% in the first quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock valued at $6,698,000 after acquiring an additional 5,148 shares in the last quarter. Simon Quick Advisors LLC bought a new position in shares of Charles River Laboratories International in the first quarter worth about $307,000. Assenagon Asset Management S.A. grew its position in shares of Charles River Laboratories International by 1,721.1% during the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after purchasing an additional 538,792 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Charles River Laboratories International by 16,153.2% during the first quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company's stock worth $40,219,000 after purchasing an additional 265,558 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 1.6%

CRL stock opened at $149.50 on Monday. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The stock has a market capitalization of $7.34 billion, a price-to-earnings ratio of 996.67, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm's fifty day simple moving average is $129.05 and its two-hundred day simple moving average is $156.80.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.27 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

CRL has been the subject of several recent analyst reports. Barclays upped their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Robert W. Baird boosted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Finally, TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $171.85.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.